Clinical analysis of drug treatment trends for coronary heart disease in China

1

Coronary heart disease (CHD) is the leading cause of mortality in China, with a significant increase in prevalence and incidence over recent decades.
2

CHD research output in China has expanded significantly, with a 760% increase in publications from 2006 to 2020, indicating growing academic interest.
3

The majority of clinical trials (76.4%) focus on bioequivalence studies, with chemical pharmaceuticals dominating over traditional Chinese medicine.
4

Critical gaps exist in CHD research, particularly in lipid metabolism targets, despite the dominance of statin therapies in clinical guidelines.
5

China's CHD research is primarily policy-driven, necessitating a strategic shift towards innovative drug trials and high-impact publication to align with global standards.

1